Halozyme Therapeutics, Inc.
High uncertainty:The valuation methods show significant disagreement (>100% spread). Treat the range as a rough guide rather than a precise estimate.
Bear Case (25th pct.)
-74.1% vs price
Base Case (Median)
-27.6% vs price
Bull Case (75th pct.)
13.5% vs price
◇ = Current price | |Bear |Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $-162.45 | -257.7% | High (40%) |
| PE Comparable | $74.55 | -27.6% | Medium (25%) |
| Growth Trajectory DCF | $99.27 | -3.6% | Medium (20%) |
| Graham Number | $5.54 | -94.6% | Medium (40%) |
| EV/EBITDA | $47.82 | -53.6% | Medium (20%) |
| EV/FCF | $134.55 | 30.6% | Medium (20%) |
| Earnings Power Value | $337.57 | 227.7% | Medium (50%) |
Based on 7 out of 8 methods, HALO appears fairly valued at the current price of $103.00. The base case fair value of $74.55 implies 27.6% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.